Master source list

Every claim on this site traces to one of three tiers: primary regulatory and clinical sources, provider-published pages, or third-party price trackers. Here's the full catalog, by tier, as of dataset v2026.08.14.

Tier one: regulatory & clinical

FDA drug shortage database (tirzepatide resolution, December 19, 2024) and FDA compounding guidance on the end of 503B bulk production (March 19, 2025) and 503A patient-specific requirements; FDA warning letters to GLP-1 telehealth marketers (February 2026); FDA-approved labeling for Zepbound and Mounjaro including the boxed warning; the SURMOUNT-1 trial (NEJM 2022 — 15%, 19.5%, and 20.9% average weight reduction at 5, 10, and 15 mg versus 3.1% placebo over 72 weeks) and SURMOUNT-5 head-to-head (tirzepatide −20.2% versus semaglutide −13.7%); CMS Medicare GLP-1 Bridge program materials and KFF's BALANCE/Bridge analysis (Jul 1 2026 – Dec 31 2027, $50 copay; covered: Wegovy all forms, Zepbound KwikPen, Foundayo); Eli Lilly's Foundayo (orforglipron) approval announcement (Apr 1, 2026) and ATTAIN-1 phase 3 results; PubMed-indexed literature on GLP-1 receptor agonist pharmacology and on oral peptide bioavailability (including SNAC-mediated oral semaglutide, ~1% bioavailability).

Tier two: provider-published pages

NexLife plan pages: tirzepatide-all-plans, semaglutide-all-plans, microdose-tirzepatide-program, microdose-semaglutide-program, sublingual-tirzepatide-odt, sublingual-semaglutide-odt (all at nexlife.us — figures also supplied directly by the operator and labeled accordingly); official pricing and program pages of Henry Meds, Mochi Health, MEDVi, Eden, Ro, Hims, Hers, LillyDirect, and other tracked providers, each recorded with retrieval date in the dataset's source_url fields.

Tier three: third-party trackers & industry reporting

Independent price-tracking and industry pages consulted for reported figures and regulatory summaries, including tirzepatide.us.com, dosemate.com, skinnyvip.com, rxpepsdirect.com, telehealthally.com, formblends.com, nationwidecompounding.com, portraitcare.com, healthon.com, and middlewaynutrition.com. Tier-three figures are always labeled reported, never verified, and conflicts between tier-three sources are displayed rather than averaged.

Trend data

Google Trends exports (US, 2026) for the tirzepatide/semaglutide query universe — the basis for the provider watchlist and the rising-query roadmap in our content plan.

A claim you can't trace? That's a correction: report it.